Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxxinity Inc VAXX

Healthcare Biotechnology
Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the... see more

Recent & Breaking News (PINL:VAXX)

Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates

GlobeNewswire March 27, 2023

Vaxxinity Joins TransCelerate Research and Development Consortium

GlobeNewswire March 21, 2023

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

GlobeNewswire March 20, 2023

Vaxxinity to Present at Upcoming March Scientific and Medical Conferences

GlobeNewswire March 2, 2023

Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida

GlobeNewswire February 1, 2023

Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2023

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

GlobeNewswire December 2, 2022

Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2022

Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022

GlobeNewswire November 3, 2022

Vaxxinity to Present at Upcoming Investor Conferences in November

GlobeNewswire November 1, 2022

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

GlobeNewswire October 24, 2022

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

GlobeNewswire September 13, 2022

Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)

GlobeNewswire September 12, 2022

Vaxxinity to Present at Upcoming Investor Conferences in September

GlobeNewswire September 1, 2022

Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

GlobeNewswire August 11, 2022

Vaxxinity to Present at the Canaccord Genuity 42nd Annual Growth Conference

GlobeNewswire August 4, 2022

Vaxxinity's Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates

GlobeNewswire August 2, 2022

Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC)

GlobeNewswire August 1, 2022

Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines

GlobeNewswire July 25, 2022

Vaxxinity to Participate at the Jefferies Healthcare Conference

GlobeNewswire June 2, 2022